Nuformix plc (LON:NFX)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.275
+0.010 (3.77%)
At close: Mar 6, 2026
30,456%
Market Cap 5.80M
Revenue (ttm) n/a
Net Income (ttm) -652.59K
Shares Out 2.11B
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,752,660
Average Volume 28,689,849
Open 0.285
Previous Close 0.265
Day's Range 0.260 - 0.294
52-Week Range 0.001 - 0.294
Beta 1.41
RSI 56.87
Earnings Date May 1, 2026

About Nuformix

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has a licensing agreement with Oxilio Ltd. for NX... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 3
Stock Exchange London Stock Exchange
Ticker Symbol NFX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.